首页 > 最新文献

Vaccine最新文献

英文 中文
A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.
Pub Date : 2024-12-06 DOI: 10.1016/j.vaccine.2024.126574
Bryan S Kaplan, Carine K Souza, J Brian Kimble, Meghan Wymore Brand, Tavis K Anderson, Phillip C Gauger, Daniel R Perez, Amy L Baker

Influenza A viruses (IAV) of subtypes H1N1, H1N2, and H3N2 are endemic in US domestic swine populations and contribute to significant economic losses annually and pose a persistent pandemic threat. Adjuvanted, whole-inactivated virus (WIV) vaccines are the primary countermeasure to control IAV in swine. The compositions of these vaccines are matched for hemagglutinin (HA) strain and content, often ignoring the other IAV glycoprotein, the neuraminidase (NA). The IAV NA is immunogenic and antibodies targeting epitopes adjacent to the active site have been shown to inhibit the sialidase activity of NA thereby reducing virus replication and shedding. To assess the ability of neuraminidase inhibiting (NAI) antibodies induced from WIV administration to protect swine from challenge with IAV containing homologous and heterologous NA, we produced WIV composed of viruses with an irrelevant mismatched H9 HA but expressing NA proteins from two predominant clades (N2-2002A.2 and N22002B.2) currently circulating in US domestic swine populations. Pigs that received two doses of H9N2 WIV developed vaccine-specific neuraminidase inhibition antibodies and when challenged with a wild-type H3N2 virus containing homologous NA, displayed reduced virus shedding in the upper respiratory tract and decreased virus titers in the lung compared to unvaccinated controls. Pigs challenged with H3N2 containing a heterologous NA also had reduced virus titers in the nasal swab and BALF samples. Together these results show that NAI antibodies cross-protected across phylogenetic clades and reduced virus replication and shedding in swine.

{"title":"A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.","authors":"Bryan S Kaplan, Carine K Souza, J Brian Kimble, Meghan Wymore Brand, Tavis K Anderson, Phillip C Gauger, Daniel R Perez, Amy L Baker","doi":"10.1016/j.vaccine.2024.126574","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126574","url":null,"abstract":"<p><p>Influenza A viruses (IAV) of subtypes H1N1, H1N2, and H3N2 are endemic in US domestic swine populations and contribute to significant economic losses annually and pose a persistent pandemic threat. Adjuvanted, whole-inactivated virus (WIV) vaccines are the primary countermeasure to control IAV in swine. The compositions of these vaccines are matched for hemagglutinin (HA) strain and content, often ignoring the other IAV glycoprotein, the neuraminidase (NA). The IAV NA is immunogenic and antibodies targeting epitopes adjacent to the active site have been shown to inhibit the sialidase activity of NA thereby reducing virus replication and shedding. To assess the ability of neuraminidase inhibiting (NAI) antibodies induced from WIV administration to protect swine from challenge with IAV containing homologous and heterologous NA, we produced WIV composed of viruses with an irrelevant mismatched H9 HA but expressing NA proteins from two predominant clades (N2-2002A.2 and N22002B.2) currently circulating in US domestic swine populations. Pigs that received two doses of H9N2 WIV developed vaccine-specific neuraminidase inhibition antibodies and when challenged with a wild-type H3N2 virus containing homologous NA, displayed reduced virus shedding in the upper respiratory tract and decreased virus titers in the lung compared to unvaccinated controls. Pigs challenged with H3N2 containing a heterologous NA also had reduced virus titers in the nasal swab and BALF samples. Together these results show that NAI antibodies cross-protected across phylogenetic clades and reduced virus replication and shedding in swine.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126574"},"PeriodicalIF":0.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
Pub Date : 2024-12-06 DOI: 10.1016/j.vaccine.2024.126535
Chenoa Sankar, Johanna C Meyer, Marione Schönfeldt, Hannah Gunter, Halima Dawood, Victoria Sekiti, Naseera Pickard, Lawrence Mubaiwa, Dini Mawela, Sipho Dlamini, Jonny Peter, David Spencer, Clive Gray, Vinod Patel, Lesley Bamford, Tohlang Sehloho, Kerrigan McCarthy

Background: Surveillance systems for monitoring and reporting adverse events following immunisation (AEFI) and adverse events of special interest (AESI) are vital in understanding safety profiles of post-marketed vaccines. Evaluation of surveillance systems is necessary for systems strengthening. We conducted the first evaluation of the South African AEFI surveillance system in its current form, established in 2018.

Methods: Using CDC guidelines for evaluation of surveillance systems, we conducted a cross-sectional evaluation of system attributes, including quantitative analyses of AEFI/AESI data from 17 May 2021 to 31 December 2022 and qualitative analyses through semi-structured interviews with AEFI surveillance personnel. Findings were used to generate recommendations for system strengthening.

Results: The system collects and manages AEFI data, employs investigative tools and has an established AEFI review committee conducting causality assessment, thus meeting WHO minimal capacity for vaccine safety. System adaptation through inclusion of digital applications facilitated public reporting, whilst increasing complexity of database management. Respondents demonstrated engagement with the system through accounts of their roles in AEFI surveillance. Between 17 May 2021 and 31 December 2022, 37,537,009 COVID-19 vaccine doses (BNT162b2 and Ad26.COV2·S) were administered, and 3846 AEFI reported in relation to these vaccines (reporting rate: 10.2/100,000 doses). AEFI reporting rates varied considerably across provinces, ranging from 1.6 to 59.5 AEFI/100,000 doses. In this time period 283 AEFI were reported in relation to non-COVID-19 vaccines. By 31 December 2022, 73.5 % of severe cases that were investigated were causality assessed.

Conclusion: We observed a functional, useful, flexible system with high reported stakeholder and public acceptability levels. System challenges included low reporting rates from particular provinces, weak co-ordination between paper and digital reporting and human resource constraints. Recommendations include integration of paper-based and digital surveillance reporting systems to enhance signal detection and eliminate data duplication, provision of dedicated human and financial resources at provincial level and inclusion of active AEFI surveillance through cohort event monitoring.

{"title":"Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.","authors":"Chenoa Sankar, Johanna C Meyer, Marione Schönfeldt, Hannah Gunter, Halima Dawood, Victoria Sekiti, Naseera Pickard, Lawrence Mubaiwa, Dini Mawela, Sipho Dlamini, Jonny Peter, David Spencer, Clive Gray, Vinod Patel, Lesley Bamford, Tohlang Sehloho, Kerrigan McCarthy","doi":"10.1016/j.vaccine.2024.126535","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126535","url":null,"abstract":"<p><strong>Background: </strong>Surveillance systems for monitoring and reporting adverse events following immunisation (AEFI) and adverse events of special interest (AESI) are vital in understanding safety profiles of post-marketed vaccines. Evaluation of surveillance systems is necessary for systems strengthening. We conducted the first evaluation of the South African AEFI surveillance system in its current form, established in 2018.</p><p><strong>Methods: </strong>Using CDC guidelines for evaluation of surveillance systems, we conducted a cross-sectional evaluation of system attributes, including quantitative analyses of AEFI/AESI data from 17 May 2021 to 31 December 2022 and qualitative analyses through semi-structured interviews with AEFI surveillance personnel. Findings were used to generate recommendations for system strengthening.</p><p><strong>Results: </strong>The system collects and manages AEFI data, employs investigative tools and has an established AEFI review committee conducting causality assessment, thus meeting WHO minimal capacity for vaccine safety. System adaptation through inclusion of digital applications facilitated public reporting, whilst increasing complexity of database management. Respondents demonstrated engagement with the system through accounts of their roles in AEFI surveillance. Between 17 May 2021 and 31 December 2022, 37,537,009 COVID-19 vaccine doses (BNT162b2 and Ad26.COV2·S) were administered, and 3846 AEFI reported in relation to these vaccines (reporting rate: 10.2/100,000 doses). AEFI reporting rates varied considerably across provinces, ranging from 1.6 to 59.5 AEFI/100,000 doses. In this time period 283 AEFI were reported in relation to non-COVID-19 vaccines. By 31 December 2022, 73.5 % of severe cases that were investigated were causality assessed.</p><p><strong>Conclusion: </strong>We observed a functional, useful, flexible system with high reported stakeholder and public acceptability levels. System challenges included low reporting rates from particular provinces, weak co-ordination between paper and digital reporting and human resource constraints. Recommendations include integration of paper-based and digital surveillance reporting systems to enhance signal detection and eliminate data duplication, provision of dedicated human and financial resources at provincial level and inclusion of active AEFI surveillance through cohort event monitoring.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126535"},"PeriodicalIF":0.0,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FTIR monitoring of the 13-valent pneumococcal conjugate vaccine for lung cancer patients: Changes in amides vibrations correlated with biochemical assays. 用于肺癌患者的 13 价肺炎球菌结合疫苗的傅立叶变换红外光谱监测:与生化检测相关的酰胺振动变化。
Pub Date : 2024-12-02 Epub Date: 2024-10-19 DOI: 10.1016/j.vaccine.2024.126459
Jolanta Smok-Kalwat, Stanisław Góźdź, Paweł Macek, Piotr Wasiński, Maryna Khalavka, Przemyslaw Raczkiewicz, Andrzej Stepulak, Joanna Depciuch

Lung cancer is one of the most lethal cancers. Unfortunately, respiratory tract infections are very common in lung cancer patients, delaying appropriate anticancer therapy. To increase therapy efficiency, in this study we examined the effect of 13-Valent Pneumococcal Conjugate Vaccine on the immune response in lung cancer patients, which indirectly affects the success of anticancer therapy. The study was done using biochemical tests and Fourier Transform InfraRed (FTIR) spectroscopy. For this purpose, serum from lung cancer patients aged 52 ± 9 years (III and IV clinical stage; 79 %; n = 103) before and seven as well as 30 days after vaccination was collected. Obtained results showed increasing concentrations of immunoglobulin IgG and IgG2 groups in patients after vaccination in comparison with group before vaccination. This result was confirmed by FTIR spectroscopy, where higher absorbances of amides vibrations were observed after vaccination. Interestingly, lack of differences in the amides absorbances between patients 7 and 30 days after vaccination were noticed. FTIR spectra also showed changes in the ratio between amide I and amide III as well as between amide II and amide III in the groups of patients after vaccination. From deconvolution of made I range (1600 cm-1-1700 cm-1) decrease of the ratio between α-helix and β-sheet around 0.05 was noticed in serum collected from patients after vaccination in comparison with patients before vaccination. Using Principal Component Analysis (PCA) analysis of FTIR data it was observed that serum collected from all three analyzed groups of samples was possible to differentiate. The highest accuracy in differentiation group of samples before and 7 days after vaccination was visible in amide I, while before and 30 days after vaccination using amide II. Correlation between immunoglobulin IgG and IgG2 concentrations obtained by biochemical assays and FTIR were noticed only in the group of serum collected 30 days after vaccination, which suggested that FTIR spectroscopy reflects biochemical data.

肺癌是最致命的癌症之一。不幸的是,呼吸道感染在肺癌患者中非常常见,从而延误了适当的抗癌治疗。为了提高治疗效率,我们在本研究中探讨了 13 价肺炎球菌结合疫苗对肺癌患者免疫反应的影响,因为免疫反应会间接影响抗癌治疗的成功与否。研究采用了生化测试和傅立叶变换红外光谱(FTIR)技术。为此,研究人员收集了 52 ± 9 岁肺癌患者(临床分期为 III 和 IV 期;79%;n = 103)在接种疫苗前、接种疫苗后 7 天和 30 天的血清。结果显示,与接种疫苗前相比,接种疫苗后患者体内免疫球蛋白 IgG 和 IgG2 组的浓度有所增加。傅立叶变换红外光谱证实了这一结果,接种疫苗后酰胺振动的吸光度更高。有趣的是,接种疫苗 7 天和 30 天后,患者的酰胺吸光度没有差异。傅立叶变换红外光谱还显示,接种疫苗后各组患者的酰胺 I 和酰胺 III 之间以及酰胺 II 和酰胺 III 之间的比例发生了变化。与接种疫苗前相比,接种疫苗后患者的血清中α-螺旋体和β-片状体之间的比例下降了约0.05。通过对傅立叶变换红外光谱数据进行主成分分析 (PCA) 发现,从所有三组分析样本中采集的血清都可以进行区分。在接种疫苗前和接种疫苗后 7 天的样本组中,酰胺 I 的分辨准确率最高,而在接种疫苗前和接种疫苗后 30 天的样本组中,酰胺 II 的分辨准确率最高。只有在接种疫苗 30 天后采集的血清组中,生化测定和傅立叶变换红外光谱法获得的免疫球蛋白 IgG 和 IgG2 浓度之间才存在相关性,这表明傅立叶变换红外光谱法反映了生化数据。
{"title":"FTIR monitoring of the 13-valent pneumococcal conjugate vaccine for lung cancer patients: Changes in amides vibrations correlated with biochemical assays.","authors":"Jolanta Smok-Kalwat, Stanisław Góźdź, Paweł Macek, Piotr Wasiński, Maryna Khalavka, Przemyslaw Raczkiewicz, Andrzej Stepulak, Joanna Depciuch","doi":"10.1016/j.vaccine.2024.126459","DOIUrl":"10.1016/j.vaccine.2024.126459","url":null,"abstract":"<p><p>Lung cancer is one of the most lethal cancers. Unfortunately, respiratory tract infections are very common in lung cancer patients, delaying appropriate anticancer therapy. To increase therapy efficiency, in this study we examined the effect of 13-Valent Pneumococcal Conjugate Vaccine on the immune response in lung cancer patients, which indirectly affects the success of anticancer therapy. The study was done using biochemical tests and Fourier Transform InfraRed (FTIR) spectroscopy. For this purpose, serum from lung cancer patients aged 52 ± 9 years (III and IV clinical stage; 79 %; n = 103) before and seven as well as 30 days after vaccination was collected. Obtained results showed increasing concentrations of immunoglobulin IgG and IgG2 groups in patients after vaccination in comparison with group before vaccination. This result was confirmed by FTIR spectroscopy, where higher absorbances of amides vibrations were observed after vaccination. Interestingly, lack of differences in the amides absorbances between patients 7 and 30 days after vaccination were noticed. FTIR spectra also showed changes in the ratio between amide I and amide III as well as between amide II and amide III in the groups of patients after vaccination. From deconvolution of made I range (1600 cm<sup>-1</sup>-1700 cm<sup>-1</sup>) decrease of the ratio between α-helix and β-sheet around 0.05 was noticed in serum collected from patients after vaccination in comparison with patients before vaccination. Using Principal Component Analysis (PCA) analysis of FTIR data it was observed that serum collected from all three analyzed groups of samples was possible to differentiate. The highest accuracy in differentiation group of samples before and 7 days after vaccination was visible in amide I, while before and 30 days after vaccination using amide II. Correlation between immunoglobulin IgG and IgG2 concentrations obtained by biochemical assays and FTIR were noticed only in the group of serum collected 30 days after vaccination, which suggested that FTIR spectroscopy reflects biochemical data.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"42 26","pages":"126459"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen. 铜绿假单胞菌延伸因子-Tu(EF-Tu)是一种免疫原性保护蛋白抗原。
Pub Date : 2024-12-02 Epub Date: 2024-10-30 DOI: 10.1016/j.vaccine.2024.126476
Dina A Moustafa, Emma Lou, Morgan E Schafer-Kestenman, Margalida Mateu-Borrás, Antonio Doménech-Sanchez, Sebastián Albertí, Joanna B Goldberg

Pseudomonas aeruginosa is a Gram-negative, opportunistic pathogen that infects immunocompromised individuals, especially in the hospital setting. This bacterium is an important pathogen in people with weakened immune systems, injuries, and other underlying physiologic dysfunctions. P. aeruginosa is responsible for up to 20 % of all hospital-acquired pneumonias. It is one of the major causes of nosocomial infections and has been noted to be one of the most common bacteria co-infecting patients with COVID-19 or causing super-infections following COVID-19 infections. Despite improvements in antimicrobial therapy and hospital care, P. aeruginosa bacteremia and pneumonia remain fatal in about 30 % of cases. P. aeruginosa is also the leading cause of chronic life-threatening lung infections in cystic fibrosis patients. This bacterium is naturally antibiotic resistant, and infections are notoriously difficult to treat once established, with no vaccine available. We have previously shown that elongation factor-Tu (EF-Tu), a protein best known for its role in protein synthesis, is surface exposed on P. aeruginosa. As this protein is highly expressed, evolutionally conserved, and essential, we hypothesized it would make a good vaccine target. In this study, we found that P. aeruginosa EF-Tu is immunogenic in people, and that mice can develop an immune response following immunization with recombinant P. aeruginosa EF-Tu. Furthermore, immunized mice were protected from subsequent P. aeruginosa pneumonia and transfer of this vaccine antisera to naïve mice resulted in decreased colonization. Altogether these findings support the consideration of EF-Tu as a new vaccine candidate against P. aeruginosa.

铜绿假单胞菌是一种革兰氏阴性机会性病原体,可感染免疫力低下的人,尤其是在医院环境中。这种细菌是免疫力低下、受伤和其他潜在生理机能障碍患者的重要病原体。在所有医院获得性肺炎中,铜绿假单胞菌的感染率高达 20%。它是引起院内感染的主要病因之一,也是合并感染 COVID-19 或在 COVID-19 感染后引起超级感染的最常见细菌之一。尽管抗菌治疗和医院护理有所改善,但仍有约 30% 的铜绿假单胞菌菌血症和肺炎病例是致命的。铜绿假单胞菌也是导致囊性纤维化患者发生危及生命的慢性肺部感染的主要原因。这种细菌天生具有抗生素耐药性,一旦感染就很难治疗,也没有疫苗可用。我们之前已经证明,铜绿假单胞菌表面暴露有伸长因子-Tu(EF-Tu),这是一种因其在蛋白质合成中的作用而最为人熟知的蛋白质。由于这种蛋白质表达量高,在进化过程中保持不变,而且是必不可少的,因此我们推测它将成为一个很好的疫苗靶标。在这项研究中,我们发现铜绿假单胞菌 EF-Tu 在人体内具有免疫原性,小鼠免疫重组铜绿假单胞菌 EF-Tu 后可产生免疫反应。此外,免疫后的小鼠在随后的铜绿假单胞菌肺炎中受到保护,将这种疫苗抗血清转移到天真小鼠身上可减少定植。总之,这些研究结果支持将 EF-Tu 作为一种新的铜绿假单胞菌候选疫苗。
{"title":"Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.","authors":"Dina A Moustafa, Emma Lou, Morgan E Schafer-Kestenman, Margalida Mateu-Borrás, Antonio Doménech-Sanchez, Sebastián Albertí, Joanna B Goldberg","doi":"10.1016/j.vaccine.2024.126476","DOIUrl":"10.1016/j.vaccine.2024.126476","url":null,"abstract":"<p><p>Pseudomonas aeruginosa is a Gram-negative, opportunistic pathogen that infects immunocompromised individuals, especially in the hospital setting. This bacterium is an important pathogen in people with weakened immune systems, injuries, and other underlying physiologic dysfunctions. P. aeruginosa is responsible for up to 20 % of all hospital-acquired pneumonias. It is one of the major causes of nosocomial infections and has been noted to be one of the most common bacteria co-infecting patients with COVID-19 or causing super-infections following COVID-19 infections. Despite improvements in antimicrobial therapy and hospital care, P. aeruginosa bacteremia and pneumonia remain fatal in about 30 % of cases. P. aeruginosa is also the leading cause of chronic life-threatening lung infections in cystic fibrosis patients. This bacterium is naturally antibiotic resistant, and infections are notoriously difficult to treat once established, with no vaccine available. We have previously shown that elongation factor-Tu (EF-Tu), a protein best known for its role in protein synthesis, is surface exposed on P. aeruginosa. As this protein is highly expressed, evolutionally conserved, and essential, we hypothesized it would make a good vaccine target. In this study, we found that P. aeruginosa EF-Tu is immunogenic in people, and that mice can develop an immune response following immunization with recombinant P. aeruginosa EF-Tu. Furthermore, immunized mice were protected from subsequent P. aeruginosa pneumonia and transfer of this vaccine antisera to naïve mice resulted in decreased colonization. Altogether these findings support the consideration of EF-Tu as a new vaccine candidate against P. aeruginosa.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"42 26","pages":"126476"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"But then that's another barrier": A qualitative study of parent and provider perspectives on rural versus urban disparities in adolescent vaccination. "但这又是一个障碍":从家长和医疗服务提供者的角度对青少年疫苗接种中的农村与城市差异进行定性研究。
Pub Date : 2024-12-02 Epub Date: 2024-10-21 DOI: 10.1016/j.vaccine.2024.126456
Sarah E Brewer, Jessica R Cataldi, Cathryn Perreira, Andrea Nederveld, Michael P Fisher, Anna Furniss, Charnetta Williams, Sean T O'Leary, Amanda F Dempsey

Purpose: Vaccination rates are significantly lower among adolescents living in rural areas compared to those living in urban areas. The objective of this study was to understand the factors contributing to disparities in vaccination between adolescents in rural compared to urban areas.

Methods: Semi-structured qualitative interviews were conducted with parents and providers in 16 rural and 4 urban counties of Colorado. Interview questions followed the socioecological model of health and addressed personal, interpersonal, community, and environment/structural barriers and facilitators that impact adolescent vaccination rates. Qualitative content analysis with a directed content analysis approach was used. Urban and rural interviews were compared to identify barriers unique to rural communities.

Findings: Reported barriers included lack of vaccine access at primary care, lack of routine preventive care utilization, the need to take off time from work and school, and misinformation about vaccines. Barriers that were unique to rural communities included structural barriers such as lack of evening and weekend appointments, providers not stocking vaccines, short provider tenures, and costs; logistical barriers such as the need for multiple visits to multiple locations and distance and travel time; and beliefs and behaviors such as an overreliance on sports physicals (in lieu of preventive visits) and natural lifestyle cultures.

Conclusions: There are unique challenges to adolescent vaccination in rural areas that contribute to fewer adolescents receiving their recommended vaccines. Addressing structural barriers may address this disparity.

目的:与城市青少年相比,农村青少年的疫苗接种率明显偏低。本研究的目的是了解造成农村地区与城市地区青少年疫苗接种率差异的因素:对科罗拉多州 16 个农村县和 4 个城市县的家长和医疗服务提供者进行了半结构化定性访谈。访谈问题遵循健康的社会生态模式,涉及影响青少年疫苗接种率的个人、人际、社区和环境/结构障碍和促进因素。采用定向内容分析法进行定性内容分析。对城市和农村的访谈进行了比较,以确定农村社区特有的障碍:所报告的障碍包括基层医疗机构缺乏疫苗接种渠道、缺乏常规预防性医疗服务、需要请假工作和上学以及关于疫苗的错误信息。农村社区特有的障碍包括结构性障碍,如缺乏晚间和周末预约、医疗服务提供者没有疫苗储备、医疗服务提供者任期较短以及费用;后勤障碍,如需要在多个地点多次就诊以及距离和旅行时间;以及信仰和行为,如过度依赖运动体检(代替预防性就诊)和自然生活方式文化:结论:农村地区的青少年接种疫苗面临着独特的挑战,导致接受推荐疫苗接种的青少年人数较少。解决结构性障碍可能会消除这种差异。
{"title":"\"But then that's another barrier\": A qualitative study of parent and provider perspectives on rural versus urban disparities in adolescent vaccination.","authors":"Sarah E Brewer, Jessica R Cataldi, Cathryn Perreira, Andrea Nederveld, Michael P Fisher, Anna Furniss, Charnetta Williams, Sean T O'Leary, Amanda F Dempsey","doi":"10.1016/j.vaccine.2024.126456","DOIUrl":"10.1016/j.vaccine.2024.126456","url":null,"abstract":"<p><strong>Purpose: </strong>Vaccination rates are significantly lower among adolescents living in rural areas compared to those living in urban areas. The objective of this study was to understand the factors contributing to disparities in vaccination between adolescents in rural compared to urban areas.</p><p><strong>Methods: </strong>Semi-structured qualitative interviews were conducted with parents and providers in 16 rural and 4 urban counties of Colorado. Interview questions followed the socioecological model of health and addressed personal, interpersonal, community, and environment/structural barriers and facilitators that impact adolescent vaccination rates. Qualitative content analysis with a directed content analysis approach was used. Urban and rural interviews were compared to identify barriers unique to rural communities.</p><p><strong>Findings: </strong>Reported barriers included lack of vaccine access at primary care, lack of routine preventive care utilization, the need to take off time from work and school, and misinformation about vaccines. Barriers that were unique to rural communities included structural barriers such as lack of evening and weekend appointments, providers not stocking vaccines, short provider tenures, and costs; logistical barriers such as the need for multiple visits to multiple locations and distance and travel time; and beliefs and behaviors such as an overreliance on sports physicals (in lieu of preventive visits) and natural lifestyle cultures.</p><p><strong>Conclusions: </strong>There are unique challenges to adolescent vaccination in rural areas that contribute to fewer adolescents receiving their recommended vaccines. Addressing structural barriers may address this disparity.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"42 26","pages":"126456"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The recombinant feline herpesvirus 1 expressing feline Calicivirus VP1 protein is safe and effective in cats. 表达猫钙病毒 VP1 蛋白的重组猫疱疹病毒 1 对猫安全有效。
Pub Date : 2024-12-02 Epub Date: 2024-10-29 DOI: 10.1016/j.vaccine.2024.126468
Aoxing Tang, Meng Zhu, Jie Zhu, Da Zhang, Shiqiang Zhu, Chunchun Meng, Chuanfeng Li, Guangqing Liu

Feline herpesvirus type 1 (FHV) and feline calicivirus (FCV) are significant pathogens causing upper respiratory tract disease in cats. Existing inactivated or modified live vaccines against FCV and FHV face limitations in safety and efficacy. To overcome these challenges, a recombinant strain FHV ΔgI/gE-FCV VP1 was developed by deleting the gI/gE gene and concurrently expressing FCV VP1, using the FHV WX19 strain as the parental virus. Results indicated the presence of FCV VP1 in FHV ΔgI/gE-FCV VP1-infected CRFK cells, confirmed through protein blotting and immunofluorescence assays and virus-like particles (VLPs) of FCV were observed using transmission electron microscopy. For efficacy in cats, each animal received intranasal vaccination with 1 mL of FHV ΔgI/gE-FCV VP1 at 106 TCID50. Following completion of vaccination on day 28, animals were exposed to a potent FCV strain. Assessments included clinical signs, nasal shedding, virus neutralizing antibodies, cytokine expression and postmortem histological testing. All vaccinations with FHV ΔgI/gE-FCV VP1 were deemed safe, with significantly reduced clinical disease scores, pathological changes and viral nasal shedding following infection and robust immune responses were induced. These findings collectively suggest the effectiveness of FHV-based recombinant vaccines in preventing FCV infections.

猫疱疹病毒 1 型 (FHV) 和猫钙病毒 (FCV) 是导致猫上呼吸道疾病的重要病原体。现有的针对 FCV 和 FHV 的灭活或改良活疫苗在安全性和有效性方面存在局限性。为了克服这些挑战,我们以 FHV WX19 株为亲本病毒,通过删除 gI/gE 基因并同时表达 FCV VP1,培育出了 FHV ΔgI/gE-FCV VP1 重组株。结果表明,经蛋白质印迹和免疫荧光检测证实,在FHV ΔgI/gE-FCV VP1感染的CRFK细胞中存在FCV VP1,并利用透射电子显微镜观察到FCV的病毒样颗粒(VLPs)。为了提高猫的疗效,每只动物鼻内接种 1 mL FHV ΔgI/gE-FCV VP1,剂量为 106 TCID50。在第 28 天完成疫苗接种后,让动物接触强效 FCV 株。评估包括临床症状、鼻腔脱落、病毒中和抗体、细胞因子表达和死后组织学检测。所有接种 FHV ΔgI/gE-FCV VP1 疫苗的动物都被认为是安全的,感染后的临床疾病评分、病理变化和病毒鼻腔脱落都明显减少,并且诱导了强有力的免疫反应。这些发现共同表明,基于FHV的重组疫苗在预防FCV感染方面是有效的。
{"title":"The recombinant feline herpesvirus 1 expressing feline Calicivirus VP1 protein is safe and effective in cats.","authors":"Aoxing Tang, Meng Zhu, Jie Zhu, Da Zhang, Shiqiang Zhu, Chunchun Meng, Chuanfeng Li, Guangqing Liu","doi":"10.1016/j.vaccine.2024.126468","DOIUrl":"10.1016/j.vaccine.2024.126468","url":null,"abstract":"<p><p>Feline herpesvirus type 1 (FHV) and feline calicivirus (FCV) are significant pathogens causing upper respiratory tract disease in cats. Existing inactivated or modified live vaccines against FCV and FHV face limitations in safety and efficacy. To overcome these challenges, a recombinant strain FHV ΔgI/gE-FCV VP1 was developed by deleting the gI/gE gene and concurrently expressing FCV VP1, using the FHV WX19 strain as the parental virus. Results indicated the presence of FCV VP1 in FHV ΔgI/gE-FCV VP1-infected CRFK cells, confirmed through protein blotting and immunofluorescence assays and virus-like particles (VLPs) of FCV were observed using transmission electron microscopy. For efficacy in cats, each animal received intranasal vaccination with 1 mL of FHV ΔgI/gE-FCV VP1 at 10<sup>6</sup> TCID<sub>50</sub>. Following completion of vaccination on day 28, animals were exposed to a potent FCV strain. Assessments included clinical signs, nasal shedding, virus neutralizing antibodies, cytokine expression and postmortem histological testing. All vaccinations with FHV ΔgI/gE-FCV VP1 were deemed safe, with significantly reduced clinical disease scores, pathological changes and viral nasal shedding following infection and robust immune responses were induced. These findings collectively suggest the effectiveness of FHV-based recombinant vaccines in preventing FCV infections.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"42 26","pages":"126468"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice. SARS-CoV-2 穗状病毒样颗粒含有流感 H1/N1 抗原,可诱导小鼠产生双重免疫力。
Pub Date : 2024-12-02 Epub Date: 2024-10-30 DOI: 10.1016/j.vaccine.2024.126463
Zalma V Sanchez-Martinez, Sergio P Alpuche-Lazcano, Matthew Stuible, Bassel Akache, Tyler M Renner, Lise Deschatelets, Renu Dudani, Blair A Harrison, Michael J McCluskie, Sabahudin Hrapovic, Julie Blouin, Xinyu Wang, Matthew Schuller, Kai Cui, Jae-Young Cho, Yves Durocher

A vaccine effective against both SARS-CoV-2 and influenza A (IAV) viruses could represent a cost-effective strategy to reduce their combined public health burden as well as potential complications arising from co-infection. Based on previous findings that full-length SARS-CoV-2 spike (S) expression can induce high-level, enveloped VLP (eVLP) production in CHO cells, we tested whether IAV H1N1 hemagglutinin (H1) and neuraminidase (N1) could also be displayed on these particles. We found that co-incorporation of the IAV surface antigens in spike VLPs (S-VLPs) was highly efficient: upon transient co-expression of S + H1 or S + H1 + N1 in CHO cells, the resulting VLPs contained similar amounts of the SARS-CoV-2 S and IAV antigens. The self-assembled bivalent (S/H1) and trivalent (S/H1/N1) VLPs released into the culture media were purified by single-step chromatography using a S-VLP affinity resin. Western blot analysis and immuno‑gold labeling transmission electron microscopy (TEM) of purified VLPs confirmed the coexistence of S, H1 and N1 antigens in the same particles. Finally, we demonstrated that two doses of adjuvanted bivalent and trivalent VLPs elicit specific functional antibodies and cellular immunity in a mouse model, suggesting potential for combined SARS-CoV-2/IAV vaccine development.

一种同时对 SARS-CoV-2 和甲型流感 (IAV) 病毒有效的疫苗可能是一种具有成本效益的策略,可减轻这两种病毒对公众健康造成的综合负担,并减少同时感染可能引起的并发症。基于之前发现的全长 SARS-CoV-2 棘突(S)表达能诱导 CHO 细胞产生高水平的包膜 VLP(eVLP),我们测试了 IAV H1N1 血凝素(H1)和神经氨酸酶(N1)是否也能在这些颗粒上显示。我们发现,IAV 表面抗原在尖峰 VLPs(S-VLPs)中的共结合是非常有效的:在 CHO 细胞中瞬时共表达 S + H1 或 S + H1 + N1 后,产生的 VLPs 含有相似数量的 SARS-CoV-2 S 抗原和 IAV 抗原。释放到培养基中的自组装二价(S/H1)和三价(S/H1/N1)VLPs通过使用S-VLP亲和树脂进行单步层析纯化。对纯化的VLPs进行的Western印迹分析和免疫金标记透射电子显微镜(TEM)证实,S、H1和N1抗原共存于同一颗粒中。最后,我们证明了在小鼠模型中,两种剂量的二价和三价 VLPs 佐剂能诱导特异性功能抗体和细胞免疫,这表明了 SARS-CoV-2/IAV 联合疫苗开发的潜力。
{"title":"SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.","authors":"Zalma V Sanchez-Martinez, Sergio P Alpuche-Lazcano, Matthew Stuible, Bassel Akache, Tyler M Renner, Lise Deschatelets, Renu Dudani, Blair A Harrison, Michael J McCluskie, Sabahudin Hrapovic, Julie Blouin, Xinyu Wang, Matthew Schuller, Kai Cui, Jae-Young Cho, Yves Durocher","doi":"10.1016/j.vaccine.2024.126463","DOIUrl":"10.1016/j.vaccine.2024.126463","url":null,"abstract":"<p><p>A vaccine effective against both SARS-CoV-2 and influenza A (IAV) viruses could represent a cost-effective strategy to reduce their combined public health burden as well as potential complications arising from co-infection. Based on previous findings that full-length SARS-CoV-2 spike (S) expression can induce high-level, enveloped VLP (eVLP) production in CHO cells, we tested whether IAV H1N1 hemagglutinin (H1) and neuraminidase (N1) could also be displayed on these particles. We found that co-incorporation of the IAV surface antigens in spike VLPs (S-VLPs) was highly efficient: upon transient co-expression of S + H1 or S + H1 + N1 in CHO cells, the resulting VLPs contained similar amounts of the SARS-CoV-2 S and IAV antigens. The self-assembled bivalent (S/H1) and trivalent (S/H1/N1) VLPs released into the culture media were purified by single-step chromatography using a S-VLP affinity resin. Western blot analysis and immuno‑gold labeling transmission electron microscopy (TEM) of purified VLPs confirmed the coexistence of S, H1 and N1 antigens in the same particles. Finally, we demonstrated that two doses of adjuvanted bivalent and trivalent VLPs elicit specific functional antibodies and cellular immunity in a mouse model, suggesting potential for combined SARS-CoV-2/IAV vaccine development.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"42 26","pages":"126463"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study. 加纳 15 岁及以上人群接种 mRNA COVID-19 疫苗的安全性:队列事件监测研究。
Pub Date : 2024-12-02 Epub Date: 2024-10-23 DOI: 10.1016/j.vaccine.2024.126460
Delese Mimi Darko, Seth Kwaku Seaneke, Eric Karikari-Boateng, Edwin Nkansah, Kwame Amponsa-Achiano, Naziru Tanko Mohamed, Harriet Affran Bonful, Richard Osei Buabeng, Adela Ashie, Abena Asamoa-Amoakohene, Jeremiah Ewudzie-Sampson, Alexander Mwinteru Derizie, Adjabui D Neimatu, Agongo A Wilfred, Comfort Ogar, Aida Hagos, George Tsey Sabblah
<p><strong>Introduction: </strong>The development of COVID-19 vaccines during the pandemic occurred with an unprecedented speed, requiring extraordinary post-approval safety monitoring to facilitate ongoing evaluation of their benefit-risk profile. In Ghana, the Food and Drugs Authority granted emergency use authorization to six of these vaccines including the two mRNA COVID-19 vaccines, namely, Pfizer-BioNTech and Moderna COVID-19 vaccines. The objective of the study was to estimate the incidence of adverse events following immunization (AEFIs) and adverse events of special interest (AESIs) in persons vaccinated with mRNA COVID-19 vaccines, and to identify factors associated with the development of AEFIs.</p><p><strong>Methods: </strong>We conducted a prospective cohort event monitoring study in seven selected static vaccination center in six of Ghana's 16 regions. The choice of regions was based on their geographical locations and the incidence rate of COVID-19 at the time of the study. The study was conducted with people aged 15 years and older who were vaccinated with mRNA COVID-19 vaccines, including pregnant women. Study participants were recruited starting in November 2021, with the last participant followed up in August 2022. Persons vaccinated were followed up on days 1, 7, and 28 post-dose 1 and up to 91 days after dose 2. AEFIs were described with the most specific, or lowest-level, term using the Medical Dictionary for Regulatory Activities (MedDRA) version 26.1. Frequencies of AEFIs after each vaccine dose and vaccination center were determined. Cox-proportional hazard regression was used to assess the independent risk factors associated with the incidence of AEFI among the participants.</p><p><strong>Results: </strong>Overall, 4678 persons who received Pfizer-BioNTech or Moderna COVID-19 vaccines from the seven vaccination centers were enrolled in the study. The mean age of participants was 32.9 years (SD ± 14.4). A total of 17.4 % (95 % CI: 16.3 % to 18.5 %) of participants experienced AEFI, with a higher incidence among Moderna COVID-19 vaccine recipients (20.4 %) compared to Pfizer-BioNTech COVID-19 vaccine recipients (14.0 %). The top five common AEFIs included injection site pain, headache, dizziness, fatigue, and fever. No serious AEFIs were reported during the study. Factors such as vaccination center and history of chronic medical conditions influenced the risk of experiencing an AEFI. Cox-proportional hazard regression revealed a 37 % lower risk of AEFI with the Pfizer-BioNTech COVID-19 vaccine compared to the Moderna COVID-19 vaccine.</p><p><strong>Conclusion: </strong>The study on mRNA COVID-19 vaccines in Ghana showed that the vaccines are tolerated well with no significant safety concerns. Reports of systemic and local events were consistent with those reported in the summary of product characteristics of the two vaccines. The study's outcome showed that there were no safety issues with mRNA COVID-19 vaccines in Ghana.
简介:COVID-19 疫苗在大流行期间以前所未有的速度得到开发,这就要求在批准后进行非常规的安全监测,以促进对其效益-风险状况的持续评估。在加纳,食品药品管理局批准了其中六种疫苗的紧急使用许可,包括两种 mRNA COVID-19 疫苗,即辉瑞生物技术公司生产的 COVID-19 疫苗和 Moderna COVID-19 疫苗。该研究的目的是估计接种 mRNA COVID-19 疫苗的人群中免疫接种后不良事件(AEFIs)和特别关注不良事件(AESIs)的发生率,并确定与 AEFIs 发生相关的因素:我们在加纳 16 个地区中的 6 个地区选定的 7 个固定疫苗接种中心开展了一项前瞻性队列事件监测研究。选择这些地区的依据是它们的地理位置和研究时 COVID-19 的发病率。研究对象为接种过 mRNA COVID-19 疫苗的 15 岁及以上人群,包括孕妇。研究参与者从 2021 年 11 月开始招募,最后一名参与者的随访时间为 2022 年 8 月。在接种第一剂疫苗后的第 1 天、第 7 天和第 28 天,以及接种第二剂疫苗后的第 91 天,对接种者进行了随访。AEFI使用《监管活动医学词典》(MedDRA)26.1版中最具体或最低级的术语进行描述。确定每个疫苗剂量和接种中心后的 AEFI 频率。采用 Cox 比例危险回归法评估与参与者 AEFI 发生率相关的独立风险因素:共有4678人在7个疫苗接种中心接种了辉瑞生物技术公司或Moderna COVID-19疫苗。参与者的平均年龄为 32.9 岁(SD ± 14.4)。共有 17.4 %(95 % CI:16.3 % 至 18.5 %)的参与者发生过 AEFI,其中 Moderna COVID-19 疫苗接种者的发生率(20.4 %)高于辉瑞生物 COVID-19 疫苗接种者(14.0 %)。最常见的五种 AEFI 包括注射部位疼痛、头痛、头晕、疲劳和发烧。研究期间未报告严重的 AEFI。疫苗接种中心和慢性病史等因素会影响发生 AEFI 的风险。Cox比例危险回归显示,与Moderna COVID-19疫苗相比,Pfizer-BioNTech COVID-19疫苗的AEFI风险低37%:在加纳进行的 mRNA COVID-19 疫苗研究表明,疫苗的耐受性良好,没有明显的安全性问题。关于全身和局部事件的报告与两种疫苗的产品特性摘要中的报告一致。研究结果表明,mRNA COVID-19 疫苗在加纳不存在安全性问题。在各国计划将 COVID-19 疫苗常规化的过程中,这项研究的结果可作为重要的宣传工具来解决疫苗犹豫不决的问题。此外,在未来的大流行病期间,主动监测研究还可作为药物警戒系统薄弱的中低收入国家 (LMIC) 开展此类研究的范例。
{"title":"Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study.","authors":"Delese Mimi Darko, Seth Kwaku Seaneke, Eric Karikari-Boateng, Edwin Nkansah, Kwame Amponsa-Achiano, Naziru Tanko Mohamed, Harriet Affran Bonful, Richard Osei Buabeng, Adela Ashie, Abena Asamoa-Amoakohene, Jeremiah Ewudzie-Sampson, Alexander Mwinteru Derizie, Adjabui D Neimatu, Agongo A Wilfred, Comfort Ogar, Aida Hagos, George Tsey Sabblah","doi":"10.1016/j.vaccine.2024.126460","DOIUrl":"10.1016/j.vaccine.2024.126460","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;The development of COVID-19 vaccines during the pandemic occurred with an unprecedented speed, requiring extraordinary post-approval safety monitoring to facilitate ongoing evaluation of their benefit-risk profile. In Ghana, the Food and Drugs Authority granted emergency use authorization to six of these vaccines including the two mRNA COVID-19 vaccines, namely, Pfizer-BioNTech and Moderna COVID-19 vaccines. The objective of the study was to estimate the incidence of adverse events following immunization (AEFIs) and adverse events of special interest (AESIs) in persons vaccinated with mRNA COVID-19 vaccines, and to identify factors associated with the development of AEFIs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a prospective cohort event monitoring study in seven selected static vaccination center in six of Ghana's 16 regions. The choice of regions was based on their geographical locations and the incidence rate of COVID-19 at the time of the study. The study was conducted with people aged 15 years and older who were vaccinated with mRNA COVID-19 vaccines, including pregnant women. Study participants were recruited starting in November 2021, with the last participant followed up in August 2022. Persons vaccinated were followed up on days 1, 7, and 28 post-dose 1 and up to 91 days after dose 2. AEFIs were described with the most specific, or lowest-level, term using the Medical Dictionary for Regulatory Activities (MedDRA) version 26.1. Frequencies of AEFIs after each vaccine dose and vaccination center were determined. Cox-proportional hazard regression was used to assess the independent risk factors associated with the incidence of AEFI among the participants.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Overall, 4678 persons who received Pfizer-BioNTech or Moderna COVID-19 vaccines from the seven vaccination centers were enrolled in the study. The mean age of participants was 32.9 years (SD ± 14.4). A total of 17.4 % (95 % CI: 16.3 % to 18.5 %) of participants experienced AEFI, with a higher incidence among Moderna COVID-19 vaccine recipients (20.4 %) compared to Pfizer-BioNTech COVID-19 vaccine recipients (14.0 %). The top five common AEFIs included injection site pain, headache, dizziness, fatigue, and fever. No serious AEFIs were reported during the study. Factors such as vaccination center and history of chronic medical conditions influenced the risk of experiencing an AEFI. Cox-proportional hazard regression revealed a 37 % lower risk of AEFI with the Pfizer-BioNTech COVID-19 vaccine compared to the Moderna COVID-19 vaccine.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The study on mRNA COVID-19 vaccines in Ghana showed that the vaccines are tolerated well with no significant safety concerns. Reports of systemic and local events were consistent with those reported in the summary of product characteristics of the two vaccines. The study's outcome showed that there were no safety issues with mRNA COVID-19 vaccines in Ghana. ","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"42 26","pages":"126460"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virtual reality for routine immunisations in needle phobic children with and without developmental disabilities: A pilot study. 虚拟现实技术用于患有或不患有发育障碍的打针恐惧症儿童的常规免疫接种:试点研究。
Pub Date : 2024-12-02 Epub Date: 2024-11-01 DOI: 10.1016/j.vaccine.2024.126481
Allya Makhijani, Narelle Jenkins, Jessica Kaufman, Monsurul Hoq, Sabine Priestley, Sonja Elia, Ian McKenzie, Andrew Davidson, Paul Leong, Teresa Lazzaro, Sarah McNab, Margie Danchin

Virtual reality for routine immunisations in needle phobic children with and without developmental disabilities: a pilot study.

Background: Virtual Reality (VR) headsets can improve needle procedure success and experiences for children, but they have not been evaluated to support immunisation in children with anxiety and behavioural challenges. This study assessed the feasibility and acceptability of VR for immunisation in children with needle phobia, including children with and without developmental disabilities.

Methods: A mixed method pilot study was conducted at the Royal Children's Hospital, Melbourne. Children with needle phobia aged 4-14 years scheduled for immunisation with distraction and conscious sedation were eligible. VR was offered to children with needle anxiety and/or developmental disabilities before and during immunisation in addition to standard care. Children and caregivers completed electronic surveys pre- and post-immunisation, followed by qualitative interviews post-immunisation. Clinicians completed post-immunisation surveys. Primary outcomes were feasibility and acceptability of VR according to children, caregivers and clinicians.

Results: Between May and December 2022, we screened 54 children and included 30; 15 with and 15 without developmental disability. Preparation to use VR took less than five minutes for most children (24/30; 80 %). Twenty nine (96 %) used VR immediately before immunisation, and 17 (57 %) continued using it during immunisation (7 with developmental disability, 10 without). Twenty seven (90 %) children were immunised successfully, with a small reduction in required sedation. Of those who used VR during immunisation, 16/17 (94 %) reported a more positive overall experience. Of those who only used VR before immunisation, 3/13 (23 %) still reported benefit. VR was therefore described as beneficial for 19/30 (63 %) participants (9 with developmental disability, 10 without). Caregivers reported willingness to use VR in future immunisation encounters for 23/30 (77 %) children (11 with developmental disability, 12 without).

Discussion: This pilot study suggests VR was feasible and acceptable for many children with needle phobia, both with and without developmental disability. These findings will inform a randomised controlled trial to assess effectiveness.

虚拟现实技术用于患有或不患有发育障碍的打针恐惧症儿童的常规免疫接种:一项试点研究:背景:虚拟现实(VR)头戴式设备可以提高针刺过程的成功率并改善儿童的体验,但尚未对其是否适用于焦虑和行为障碍儿童的免疫接种进行评估。本研究评估了虚拟现实技术在针头恐惧症儿童(包括有和没有发育障碍的儿童)免疫接种中的可行性和可接受性:方法:在墨尔本皇家儿童医院开展了一项混合方法试点研究。患有打针恐惧症的 4-14 岁儿童均符合条件,他们计划在分散注意力和有意识镇静的情况下接受免疫接种。在免疫接种前和免疫接种过程中,除标准护理外,还为患有打针焦虑症和/或发育障碍的儿童提供 VR。儿童和护理人员在免疫接种前和免疫接种后完成电子调查,然后在免疫接种后进行定性访谈。临床医生完成免疫接种后调查。主要结果是儿童、护理人员和临床医生对 VR 的可行性和可接受性的评价:2022 年 5 月至 12 月间,我们对 54 名儿童进行了筛查,并纳入了 30 名儿童;其中 15 名有发育障碍,15 名无发育障碍。大多数儿童(24/30;80%)使用虚拟现实的准备时间不超过五分钟。29 名儿童(96%)在免疫接种前立即使用了 VR,17 名儿童(57%)在免疫接种期间继续使用 VR(7 名发育障碍儿童,10 名非发育障碍儿童)。27 名(90%)儿童成功接种了疫苗,所需的镇静剂也略有减少。在免疫接种过程中使用虚拟现实技术的儿童中,16/17(94%)表示总体体验更加积极。在那些只在免疫接种前使用过虚拟现实技术的儿童中,3/13(23%)的儿童表示仍能从中受益。因此,19/30(63 %)的参与者(9 人有发育障碍,10 人没有发育障碍)认为虚拟现实技术对他们有益。23/30 (77 %) 名儿童(11 名发育障碍儿童,12 名非发育障碍儿童)的护理人员表示愿意在今后的免疫接种中使用 VR:讨论:这项试点研究表明,对于许多患有针刺恐惧症的儿童(包括有发育障碍和无发育障碍的儿童)来说,VR 是可行的,也是可以接受的。这些发现将为随机对照试验的有效性评估提供参考。
{"title":"Virtual reality for routine immunisations in needle phobic children with and without developmental disabilities: A pilot study.","authors":"Allya Makhijani, Narelle Jenkins, Jessica Kaufman, Monsurul Hoq, Sabine Priestley, Sonja Elia, Ian McKenzie, Andrew Davidson, Paul Leong, Teresa Lazzaro, Sarah McNab, Margie Danchin","doi":"10.1016/j.vaccine.2024.126481","DOIUrl":"10.1016/j.vaccine.2024.126481","url":null,"abstract":"<p><p>Virtual reality for routine immunisations in needle phobic children with and without developmental disabilities: a pilot study.</p><p><strong>Background: </strong>Virtual Reality (VR) headsets can improve needle procedure success and experiences for children, but they have not been evaluated to support immunisation in children with anxiety and behavioural challenges. This study assessed the feasibility and acceptability of VR for immunisation in children with needle phobia, including children with and without developmental disabilities.</p><p><strong>Methods: </strong>A mixed method pilot study was conducted at the Royal Children's Hospital, Melbourne. Children with needle phobia aged 4-14 years scheduled for immunisation with distraction and conscious sedation were eligible. VR was offered to children with needle anxiety and/or developmental disabilities before and during immunisation in addition to standard care. Children and caregivers completed electronic surveys pre- and post-immunisation, followed by qualitative interviews post-immunisation. Clinicians completed post-immunisation surveys. Primary outcomes were feasibility and acceptability of VR according to children, caregivers and clinicians.</p><p><strong>Results: </strong>Between May and December 2022, we screened 54 children and included 30; 15 with and 15 without developmental disability. Preparation to use VR took less than five minutes for most children (24/30; 80 %). Twenty nine (96 %) used VR immediately before immunisation, and 17 (57 %) continued using it during immunisation (7 with developmental disability, 10 without). Twenty seven (90 %) children were immunised successfully, with a small reduction in required sedation. Of those who used VR during immunisation, 16/17 (94 %) reported a more positive overall experience. Of those who only used VR before immunisation, 3/13 (23 %) still reported benefit. VR was therefore described as beneficial for 19/30 (63 %) participants (9 with developmental disability, 10 without). Caregivers reported willingness to use VR in future immunisation encounters for 23/30 (77 %) children (11 with developmental disability, 12 without).</p><p><strong>Discussion: </strong>This pilot study suggests VR was feasible and acceptable for many children with needle phobia, both with and without developmental disability. These findings will inform a randomised controlled trial to assess effectiveness.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"42 26","pages":"126481"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study. 在一项三期临床研究中,基于改良安卡拉疫苗载体的多价 RSV 疫苗显示出对老年人 RSV 引起的疾病具有适度的保护作用。
Pub Date : 2024-12-02 Epub Date: 2024-10-25 DOI: 10.1016/j.vaccine.2024.126427
Elke Jordan, Victoria Jenkins, Günter Silbernagl, Maria Paulina Velasco Chávez, Darja Schmidt, Frauke Schnorfeil, Stephanie Schultz, Liddy Chen, Fernanda Salgado, Jeanne-Marie Jacquet, Tobias Welte, Laurence De Moerlooze

Respiratory syncytial virus (RSV) causes a significant disease burden in older adults. The live recombinant vaccine based on a nonreplicating modified vaccinia Ankara (MVA-BN) poxvirus, MVA-BN-RSV, encoding for multiple proteins of RSV subtypes A and B, was assessed for efficacy against respiratory disease caused by RSV. Adults aged ≥60 years, with or without underlying chronic conditions, were enrolled and randomized in a 1:1 ratio to receive a single dose of vaccine or placebo and were followed for disease caused by RSV infection during the 2022-2023 season. The 2 primary endpoints were RSV-associated lower respiratory tract disease (LRTD) with ≥3 and ≥ 2 symptoms; acute respiratory disease (ARD) was a key secondary endpoint. The humoral RSV-specific immune response was assessed at baseline and 14 days post-vaccination. Safety was evaluated by collection of solicited adverse events (AEs) and unsolicited AEs for 7 and 28 days post-vaccination respectively, and SAEs for the entire study period. In total, 18,348 participants were included in the final efficacy and safety analyses. Vaccine efficacy was 42.9 % (95 % CI: -16.1; 71.9) against RSV-associated LRTD with ≥3 symptoms, 59.0 % (95 % CI: 34.7; 74.3) against LRTD with ≥2 symptoms, and 48.8 % (95 % CI: 25.8; 64.7) against ARD. The primary objective was not met for LRTD with ≥3 symptoms since the lower bound of the 95 % CI was below 20 %, the prespecified success criterion. The vaccine-elicited immune response showed mean fold-increases of 1.7 for RSV A and B neutralizing antibodies and 2.9 and 4.3 for RSV-specific IgG and IgA, respectively. The vaccine displayed mild to moderate reactogenicity, and no safety concerns were identified. MVA-BN-RSV induced suboptimal protection against RSV-associated LRTD, likely due to suboptimal neutralizing antibody response. The vaccine had an acceptable safety profile and confirmed immunogenicity, overall showing promise for MVA-BN-vectored constructs targeting other diseases. Trial Registration:Clinicaltrials.gov Identifier NCT05238025 (Registered February 14, 2022).

呼吸道合胞病毒(RSV)给老年人带来了沉重的疾病负担。我们评估了基于非复制改良安卡拉疫苗(MVA-BN)痘病毒的重组活疫苗 MVA-BN-RSV(编码 RSV A 和 B 亚型的多种蛋白)对 RSV 引起的呼吸道疾病的疗效。年龄≥60岁、患有或不患有基础慢性疾病的成人被纳入研究,并按1:1的比例随机分配接受单剂量疫苗或安慰剂,并在2022-2023年期间对RSV感染引起的疾病进行随访。两个主要终点是RSV相关的下呼吸道疾病(LRTD),症状≥3和≥2;急性呼吸道疾病(ARD)是关键的次要终点。体液 RSV 特异性免疫反应在基线和接种后 14 天进行评估。安全性通过收集接种后 7 天和 28 天的主动不良事件 (AE) 和非主动不良事件以及整个研究期间的 SAE 进行评估。共有 18348 名参与者参与了最终的有效性和安全性分析。疫苗对≥3 种症状的 RSV 相关 LRTD 的有效率为 42.9% (95 % CI: -16.1; 71.9),对≥2 种症状的 LRTD 的有效率为 59.0% (95 % CI: 34.7; 74.3),对 ARD 的有效率为 48.8% (95 % CI: 25.8; 64.7)。由于 95 % CI 的下限低于 20%,即预设的成功标准,因此症状≥3 的 LRTD 未达到主要目标。疫苗诱导的免疫反应显示,RSV A 型和 B 型中和抗体的平均增加倍数分别为 1.7 倍,RSV 特异性 IgG 和 IgA 的平均增加倍数分别为 2.9 倍和 4.3 倍。疫苗的致反应性为轻度至中度,未发现安全性问题。MVA-BN-RSV 对 RSV 相关 LRTD 的保护效果不理想,这可能是由于中和抗体反应不理想造成的。该疫苗的安全性可接受,免疫原性也得到了证实,总体上显示了针对其他疾病的 MVA-BN 病毒构建物的前景。试验注册:Clinicaltrials.gov Identifier NCT05238025(2022年2月14日注册)。
{"title":"A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.","authors":"Elke Jordan, Victoria Jenkins, Günter Silbernagl, Maria Paulina Velasco Chávez, Darja Schmidt, Frauke Schnorfeil, Stephanie Schultz, Liddy Chen, Fernanda Salgado, Jeanne-Marie Jacquet, Tobias Welte, Laurence De Moerlooze","doi":"10.1016/j.vaccine.2024.126427","DOIUrl":"10.1016/j.vaccine.2024.126427","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) causes a significant disease burden in older adults. The live recombinant vaccine based on a nonreplicating modified vaccinia Ankara (MVA-BN) poxvirus, MVA-BN-RSV, encoding for multiple proteins of RSV subtypes A and B, was assessed for efficacy against respiratory disease caused by RSV. Adults aged ≥60 years, with or without underlying chronic conditions, were enrolled and randomized in a 1:1 ratio to receive a single dose of vaccine or placebo and were followed for disease caused by RSV infection during the 2022-2023 season. The 2 primary endpoints were RSV-associated lower respiratory tract disease (LRTD) with ≥3 and ≥ 2 symptoms; acute respiratory disease (ARD) was a key secondary endpoint. The humoral RSV-specific immune response was assessed at baseline and 14 days post-vaccination. Safety was evaluated by collection of solicited adverse events (AEs) and unsolicited AEs for 7 and 28 days post-vaccination respectively, and SAEs for the entire study period. In total, 18,348 participants were included in the final efficacy and safety analyses. Vaccine efficacy was 42.9 % (95 % CI: -16.1; 71.9) against RSV-associated LRTD with ≥3 symptoms, 59.0 % (95 % CI: 34.7; 74.3) against LRTD with ≥2 symptoms, and 48.8 % (95 % CI: 25.8; 64.7) against ARD. The primary objective was not met for LRTD with ≥3 symptoms since the lower bound of the 95 % CI was below 20 %, the prespecified success criterion. The vaccine-elicited immune response showed mean fold-increases of 1.7 for RSV A and B neutralizing antibodies and 2.9 and 4.3 for RSV-specific IgG and IgA, respectively. The vaccine displayed mild to moderate reactogenicity, and no safety concerns were identified. MVA-BN-RSV induced suboptimal protection against RSV-associated LRTD, likely due to suboptimal neutralizing antibody response. The vaccine had an acceptable safety profile and confirmed immunogenicity, overall showing promise for MVA-BN-vectored constructs targeting other diseases. Trial Registration:Clinicaltrials.gov Identifier NCT05238025 (Registered February 14, 2022).</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"42 26","pages":"126427"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Vaccine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1